Hikma Pharmaceuticals USA, Inc. FDA Inspection Record

FEI 2250102 · Inspections, Form 483s, warning letters and import refusals

Hikma Pharmaceuticals USA, Inc. is an FDA-inspected facility (FEI 2250102) located in Eatontown, NJ, US. RegDataLab tracks 13 FDA inspections and 1 compliance action at this facility.

What FDA found at this site

Latest inspection
Feb 1, 2019: No Action Indicated (NAI)
Inspections on record
13 (2 OAI, 5 VAI, 6 NAI)
Last OAI inspection
Jun 7, 2013
Warning letters
1 listed by FDA for this FEI, latest Feb 6, 2012
Recalls as the recalling firm
42, latest Nov 6, 2017
Import refusals
4

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Showing the 10 most recent of 13 inspections. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Feb 1, 2019No Action Indicated (NAI)No citations listed
Apr 13, 2018No Action Indicated (NAI)No citations listed
Jul 7, 2016No Action Indicated (NAI)No citations listed
Sep 10, 2015No Action Indicated (NAI)No citations listed
Feb 26, 2014Voluntary Action Indicated (VAI)Extent of discrepancy, failure investigations (21 CFR 211.192)
Jun 7, 2013Official Action Indicated (OAI)No citations listed
Aug 28, 2012No Action Indicated (NAI)No citations listed
Jun 30, 2011Official Action Indicated (OAI)Equipment Design, Size and Location (21 CFR 211.63)
Written procedures not established/followed (21 CFR 211.67(b))
Absence of Written Procedures (21 CFR 211.100(a))
Establishment of time limitations (21 CFR 211.111)
and 6 more
Mar 25, 2011Voluntary Action Indicated (VAI)Failure to review ADE information (21 CFR 314.80(b))
Feb 17, 2011Voluntary Action Indicated (VAI)Labeling and packaging improperly approved/released (21 CFR 211.122(b))

Recalls

Showing the 10 most recent of 42 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Nov 6, 2017Class IIID-0093-2018Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01)… and 1 more product
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).
Nov 17, 2016Class IIID-0172-2017SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTION, 62.5mg elemental iron/5mL, 10 (5mL…
Subpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.
Nov 4, 2016Class IIID-0147-2017Amoxicillin for Oral suspension, USP 400 mg/5 mL, 100 mL (when reconstituted), Rx only…
Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.
Oct 3, 2016Class IID-1045-2017Phenobarbital Tablets, USP 60mg 100=count bottles, Rx Only, Mfd. by: West-Ward…
Failed Dissolution Specifications: Phenobarbital Tablets have an out of specification for dissolution at the 12 month stability time point
Aug 18, 2016Class IIID-1515-2016Amoxicillin For Oral Suspension, USP - Dye Free, 400 mg/5 mL, 100 mL (when reconstituted)…
Labeling: Label Error on Declared Strength- bottles missing colored coded panel where strength of the product is displayed.
May 13, 2015Class IIID-1139-2015Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL), Rx Only, For IV or…
Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).
Oct 2, 2014Class IID-0172-2015VERSAPHARM INCORPORATED Ethambutol Hydrochloride Tablets, USP, 100 mg, 100-count bottle…
Subpotency: Out of Specification (OOS) result at the 36 month routine stability time point.
May 20, 2014Class IID-1414-2014Isoniazid Tablets, USP, 300 mg, Rx only, packaged in a) 100-count bottles, NDC…
Failed Dissolution Specifications: Stability lots cannot support dissolution past the 36 month time point.
Nov 7, 2013Class IID-367-2014Carisoprodol Tablets, USP 350 mg, Rx Only, 1000 tablets. Dist by: West-ward…
Presence of Foreign Substance; heavy metals (chromium, titanium etc) and inactive components of the product were visually observed during…
Sep 23, 2013Class IID-66447-001Irinotecan Hydrochloride Injection, 40 mg/2 mL (20 mg/mL), 1 x 2 mL Single Dose Vial per… and 1 more product
Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in…

FDA record score

0 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 16, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

37 records behind this number
RecordDatePoints x age weightAdds
Class II recall D-1045-2017, this FEI as the recalling firmOct 3, 201610 years or older, so it adds no points0
Class II recall D-0172-2015, this FEI as the recalling firmOct 2, 201410 years or older, so it adds no points0
Class II recall D-1414-2014, this FEI as the recalling firmMay 20, 201410 years or older, so it adds no points0
Inspection classified VAIFeb 26, 201410 years or older, so it adds no points0
Class II recall D-367-2014, this FEI as the recalling firmNov 7, 201310 years or older, so it adds no points0
Class II recall D-66447-001, this FEI as the recalling firmSep 23, 201310 years or older, so it adds no points0
Class II recall D-853-2013, this FEI as the recalling firmJul 30, 201310 years or older, so it adds no points0
Class II recall D-883-2013, this FEI as the recalling firmJul 30, 201310 years or older, so it adds no points0
Inspection classified OAIJun 7, 201310 years or older, so it adds no points0
Class II recall D-839-2013, this FEI as the recalling firmJun 4, 201310 years or older, so it adds no points0
Class II recall D-824-2013, this FEI as the recalling firmMay 16, 201310 years or older, so it adds no points0
Class II recall D-242-2013, this FEI as the recalling firmMar 18, 201310 years or older, so it adds no points0
Class II recall D-306-2013, this FEI as the recalling firmMar 18, 201310 years or older, so it adds no points0
Class II recall D-220-2013, this FEI as the recalling firmFeb 6, 201310 years or older, so it adds no points0
Class II recall D-170-2013, this FEI as the recalling firmJan 7, 201310 years or older, so it adds no points0
Class II recall D-130-2013, this FEI as the recalling firmDec 7, 201210 years or older, so it adds no points0
Class II recall D-150-2013, this FEI as the recalling firmDec 7, 201210 years or older, so it adds no points0
Class II recall D-133-2013, this FEI as the recalling firmDec 5, 201210 years or older, so it adds no points0
Class II recall D-149-2013, this FEI as the recalling firmDec 5, 201210 years or older, so it adds no points0
Class II recall D-174-2013, this FEI as the recalling firmDec 4, 201210 years or older, so it adds no points0
Class II recall D-132-2013, this FEI as the recalling firmNov 30, 201210 years or older, so it adds no points0
Class II recall D-189-2013, this FEI as the recalling firmNov 30, 201210 years or older, so it adds no points0
Class II recall D-1437-2012, this FEI as the recalling firmApr 13, 201210 years or older, so it adds no points0
Warning letter on FDA's dashboard, which does not show close-outsFeb 6, 201210 years or older, so it adds no points0
Class II recall D-1276-2012, this FEI as the recalling firmJan 24, 201210 years or older, so it adds no points0
Inspection classified OAIJun 30, 201110 years or older, so it adds no points0
Class II recall D-223-2012, this FEI as the recalling firmMay 19, 201110 years or older, so it adds no points0
Inspection classified VAIMar 25, 201110 years or older, so it adds no points0
Inspection classified VAIFeb 17, 201110 years or older, so it adds no points0
Class II recall D-280-2011, this FEI as the recalling firmJan 25, 201110 years or older, so it adds no points0
Class II recall D-884-2010, this FEI as the recalling firmJun 4, 201010 years or older, so it adds no points0
Inspection classified VAIJun 1, 201010 years or older, so it adds no points0
Class II recall D-494-2010, this FEI as the recalling firmMar 9, 201010 years or older, so it adds no points0
Class II recall D-370-2010, this FEI as the recalling firmJan 8, 201010 years or older, so it adds no points0
Inspection classified VAIMay 19, 200910 years or older, so it adds no points0
Class II recall D-200-2009, this FEI as the recalling firmJan 14, 200910 years or older, so it adds no points0
Class II recall D-237-6, this FEI as the recalling firmMar 23, 200610 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Hikma Pharmaceuticals USA, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Hikma Pharmaceuticals USA, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Hikma Pharmaceuticals USA, Inc.
Location
Eatontown, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.